Last reviewed · How we verify
Comparator: naproxen sodium
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | Comparator: naproxen sodium |
|---|---|
| Also known as | naproxen sodium |
| Sponsor | Organon and Co |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology, Inflammation |
| Phase | Phase 3 |
Mechanism of action
Naproxen sodium blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses and pain signaling. The sodium salt formulation allows for faster absorption and more rapid onset of action compared to naproxen base. This mechanism makes it effective for acute and chronic pain relief, particularly in inflammatory conditions.
Approved indications
- Mild to moderate pain
- Rheumatoid arthritis
- Osteoarthritis
- Menstrual cramps
- Fever
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Abdominal pain
- Headache
- Dizziness
- Increased cardiovascular risk (with chronic use)
- Renal impairment (with chronic use)
Key clinical trials
- An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) (PHASE3)
- A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) (PHASE3)
- Colchicine Or Naproxen Treatment for ACute gouT (PHASE4)
- Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001 (PHASE1)
- A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231) (PHASE4)
- Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks (PHASE3)
- Treximet Early Intervention Adolescent Migraine (PHASE2, PHASE3)
- Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |